Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 12/20 | 0.58 |
| ▸ | JAK3 | P52333 | 6/20 | 0.58 |
| ▸ | SYK | P43405 | 5/20 | 0.52 |
| ▸ | JAK2 | O60674 | 3/20 | 0.46 |
| ▸ | TYK2 | P29597 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 3/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3111670 | 0.92 | JAK1 (0.58) | JAK1JAK3SYKJAK2TYK2 | |
| SCHEMBL3118461 | 0.89 | JAK1 (0.48) | JAK1JAK3SYKJAK2TYK2 | |
| SCHEMBL3114853 | 0.87 | SYK (0.48) | JAK1JAK3SYKJAK2TYK2 | |
| SCHEMBL14553232 | 0.86 | JAK1 (0.46) | JAK1JAK3SYKJAK2TYK2 | |
| SCHEMBL3116796 | 0.83 | JAK1 (0.44) | JAK1JAK3SYKJAK2TYK2 | |
| SCHEMBL3103946 | 0.81 | JAK1 (0.46) | JAK1JAK3SYKJAK2TYK2 | |
| SCHEMBL4282180 | 0.80 | BRD4 (0.40) | JAK1JAK3SYKBRD4 | |
| SCHEMBL4286938 | 0.80 | BRD4 (0.40) | JAK1JAK3SYKBRD4 | |
| SCHEMBL12694674 | 0.79 | JAK1 (0.48) | JAK1JAK3SYKJAK2TYK2 | |
| SCHEMBL4284314 | 0.78 | PAK1 (0.39) | JAK1JAK3SYKJAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382210-B1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9040527-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040527-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040527-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8518937-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518937-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518937-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-8278299-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278299-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278299-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | JAK1 567/4885JAK3 1186/4885SYK 2106/4885 |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | JAK1 503/4885JAK3 1030/4885SYK 2304/4885 |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | JAK1 567/4885JAK3 1186/4885SYK 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.